C-BYOJGenescient
evolutionary genomics, selective screening, Drosophila
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-BYOJ
C-BYOJC-BYOJevolutionary genomics, selective screening, Drosophila
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Genescient states that it is a new biology company using genomics together with massive selective screening to analyze, penetrate, and exploit whole genomes in order to develop novel therapeutics, with its research specifically focused on substances aimed at the chronic diseases of aging.
SourceGenescient states that its core belief is that deliberately selected laboratory animals and clinical patient databases can be used together to identify key genomic pathways that control major chronic human diseases, and that these shared pathways can be turned into effective therapeutics through large-scale screening. The company presents this as the basis for two product directions: supplements intended to maintain and improve health over time, and physician-supervised emergency pharmaceuticals intended to save patients near death.
SourceGenescient states that it is a new-generation biotechnology company using evolutionary genomics and massive selective screening across model animal and human genomes to identify exploitable genetics and develop novel therapeutics for the chronic diseases of aging. It also presents aging as a genomics problem, arguing that aging is not merely damage accumulation or faulty higher-order signaling, but results from a lack of adaptive genomic information needed for survival later in life.
Source